Medicine
Pyquvi 22.75 mg/mL oral suspension
Pyquvi 22.75 mg/mL oral suspension is a prescription medicine containing Deflazacort for oral use, marketed by Aucta Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Deflazacort
- Brand
- Pyquvi
- Strength
- 22.75 mg/mL
- Dosage form
- Oral suspension
- Route
- Oral
- Packs
- 13 mL
- Marketing authorisation holder
- Aucta Pharmaceuticals
- Manufacturer
- Aucta Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H02AB13 Deflazacort
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 June 2025
- Identifiers
- RxCUI 1870964, 2719198DailyMed set ID 39854f19-d8be-6438-e063-6394a90a9422NDC 73289-0089Application ANDA219417
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 13 mL in 1 bottle | 73289-0089-1 | Aucta Pharmaceuticals | 30 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 February 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Deflazacort 22.75 mg/mL oral suspension.
- Deflazacort 22.75 mg/mL oral suspensionAvailable on request—US FDA4 packs
- Emflaza 22.75 mg/mL oral suspensionAvailable on requestPTC TherapeuticsUS FDA1 pack
- JAYTHARI Oral Suspension 22.75 mg/mL oral suspensionAvailable on requestZydus LifesciencesIndiaUS FDA1 pack
- Kymbee 22.75 mg/mL oral suspensionAvailable on requestUpsher-Smith LaboratoriesUS FDA1 pack
Other strengths and forms of Deflazacort
Clinical summary
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. It is available as tablets and oral suspension. MedsAcross supplies Deflazacort for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeflazacortFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMFLAZA prescribing information (PTC Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Pyquvi 22.75 mg/mL oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.